Cancer BiologybioRxivPreprint
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints
A. C. Cannon, K. Budagyan, C. Uribe-Alvarez…·J. Chernoff
This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.
DOI 10.1101/2023.06.27.546707